• About Us
    • Contact Us
    • Login
    • ObGFirst
  • Alerts
  • OB
  • 2T US Atlas
  • The Genome
  • GYN
    • GYN
    • Sexual Health
  • Primary Care
  • Your Practice
  • GrandRounds
  • My Bookshelf
  • COVID-19
About Us Contact Us Login ObGFirst
  • Alerts
  • OB
  • 2T US Atlas
  • The Genome
  • GYN
    • GYN
    • Sexual Health
  • Primary Care
  • Your Practice
  • GrandRounds
  • My Bookshelf
  • COVID-19
Grand Rounds

Does Early Accelerated Fetal Growth Increase the Risk for LGA and Macrosomia?

image_pdfFavoriteLoadingFavorite

BACKGROUND AND PURPOSE:

  • Majority of studies on large-for-gestational-age (LGA) and macrosomia have focused on relationship with maternal diabetes and maternal weight
  • Common assumptions include biological variation in growth early in pregnancy being more limited and of less consequence than later in pregnancy
  • Simic et al. (Acta Obstet Gynecol Scand, 2017) examined whether accelerated fetal growth in early pregnancy was associated with risk of severe LGA and macrosomia at birth

METHODS:

  • Low-risk population cohort study
  • Population: Women with non-anomalous singleton pregnancies without history of diabetes or hypertension
  • Exposure: Growth discrepancy at early second-trimester ultrasound expressed in days
  • Discrepancy in growth: Defined as the difference in days between fetal age estimated by early second-trimester scan and expected gestational age based on the first-trimester scan
  • Gestational age calculated using fetal biparietal diameter (BPD) in both first and second trimester using and Selbing and Kjessler formula (gestational age = 58.65 + [1.07 x BPD] + (0.0138 x BPD2)
  • LGA: Birthweight for gestational age according to gestational age and fetal sex, > 97th centile
  • Macrosomia: birthweight ≥4500 g at term (≥ 37 weeks)
  • Multivariable logistic regression was used to estimate the link between accelerated growth in first trimester through early second trimester and LGA and macrosomia at birth
    • Odds ratio (OR) adjusted for maternal age, body mass index, height, parity, in vitro fertilization, smoking, and country of birth
    • Restricted analyses were performed in groups without gestational diabetes and with normal body mass index

RESULTS:

  • 68,771 pregnancies were eligible for the study
  • Compared with fetuses with a discrepancy of no more than 2 days at early second-trimester ultrasound, fetuses with ≥7-day discrepancy had an increased risk for severe LGA
    • Adjusted OR 1.80 (95% CI 1.23–2.64)
    • In pregnancies limited to those without GDM, OR 1.78 (95% CI 1.2-2.64)
  • Compared with fetuses with a discrepancy of no more than 2 days at early second-trimester ultrasound, fetuses with ≥7-day discrepancy had an increased risk for macrosomia
    • Adjusted OR 2.15 (95% CI 1.55-2.98)
    • In pregnancies limited to those without GDM, OR 2.12 (1.54-2.95)

CONCLUSION:

  • In low-risk population, ultrasound-estimated accelerated fetal growth in second trimester was associated with an 80% increased risk of severe LGA and over double the risk for a macrosomic infant
  • The authors conclude that accelerated fetal growth early in pregnancy is a risk factor for LGA and macrosomia in women in a low risk population and can be used to identify at-risk pregnancies early on

Learn More – Primary Sources:

Accelerated fetal growth in early pregnancy and risk of severe large- for- gestational-age and macrosomic infant: a cohort study in a low-risk population

image_pdfFavoriteLoadingFavorite

< Previous
All Grand Rounds Posts
Next >

Related ObG Topics:

Can Abdominal Circumference Alone Be Used to Predict SGA or LGA Newborns?
Is There an Association Between High or Low Weight Gain and Maternal and Infant Outcomes?
Macrosomia: Determination of EFW and Recommendations for Delivery

Sections

  • Alerts
  • OB
  • GYN
    • GYN
    • Sexual Health
  • 2T US Atlas
  • The Genome
  • Primary Care
  • Your Practice
  • Grand Rounds
  • My Bookshelf
  • COVID-19

Are you an
ObG Insider?

Get specially curated clinical summaries delivered to your inbox every week for free

  • Site Map/
  • © ObG Project/
  • Terms and Conditions/
  • Privacy/
  • Contact Us/
© ObG Project
SSL Certificate


  • Already an ObGFirst Member?
    Welcome back

    Log In

    Want to sign up?
    Get guideline notifications
    CME Included

    Sign Up

Sign In

Lost your password?

Sign Up for ObGFirst and Stay Ahead

  • - Professional guideline notifications
  • - Daily summary of a clinically relevant
    research paper
  • - Includes 1 hour of CME every month

ObGFirst Free Trial

Already a Member of ObGFirst®?

Please log in to ObGFirst to access the 2T US Atlas

Password Trouble?

Not an ObGFirst® Member Yet?

  • - Access 2T US Atlas
  • - Guideline notifications
  • - Daily research paper summaries
  • - And lots more!
ObGFirst Free Trial

Media - Internet

Computer System Requirements

OBG Project CME requires a modern web browser (Internet Explorer 10+, Mozilla Firefox, Apple Safari, Google Chrome, Microsoft Edge). Certain educational activities may require additional software to view multimedia, presentation, or printable versions of their content. These activities will be marked as such and will provide links to the required software. That software may be: Adobe Flash, Apple QuickTime, Adobe Acrobat, Microsoft PowerPoint, Windows Media Player, or Real Networks Real One Player.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information
presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Jointly provided by

NOT ENOUGH CME HOURS

It appears you don't have enough CME Hours to take this Post-Test. Feel free to buy additional CME hours or upgrade your current CME subscription plan

Subscribe

JOIN OBGFIRST AND GET CME/CE CREDITS

One of the benefits of an ObGFirst subscription is the ability to earn CME/CE credits from the ObG entries you read. Tap the button to learn more about ObGFirst

Learn More
Leaving ObG Website

You are now leaving the ObG website and on your way to PRIORITY at UCSF, an independent website. Therefore, we are not responsible for the content or availability of this site